Skip to content

Inspection Record

Qingdao Kangyuan Pharmaceutical Co., LTD — FDA 483 Findings

US FDAInspected 2024-08-16Published 2026-11-13 3 findingsLaboratory and QC controlsOther quality systemDocumentation and records

Inspectors Alan A. Rivera · Chad RiceThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Laboratory controls do not include scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that raw materials conform to established standards of quality and/or purity.

2Other quality system

Failure to validate and verify the suitability of analytical methods.

3Documentation and records

The master batch production record lacks an established time limit and detailed production instructions to ensure the quality of intermediates and APIs are met for individual processing steps and/or total process.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Qingdao Kangyuan Pharmaceutical Co., LTD findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.